New drug shows promise for rare joint tumor
NCT ID NCT04488822
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests the drug pexidartinib in 40 adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that causes pain and limits movement. The study focuses on people whose tumors are severe and cannot be helped by surgery. Researchers are measuring how many participants see their tumors shrink after 25 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pexidartinib (TURALIO)
- What this could lead to
- If successful, pexidartinib could offer a non-surgical treatment option for people with symptomatic TGCT that is difficult to operate on.
- What could go wrong
- This is a small, single-arm study with no placebo group, so results may be less reliable. Pexidartinib also has known risks, including liver toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Ji Shui Tan Hospital
Beijing, China
-
Fudan University Shanghai Cancer Center
Shanghai, China
-
National Taiwan University Hospital
Taipei, Taiwan
-
Peking University Cancer Hospital
Beijing, China
-
Shanghai General Hospital
Shanghai, China
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
-
Zhejiang Cancer Hospital
Hangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill shows promise for rare joint tumor in early trial
- New pill for tough tumors enters human testing
- New pill could shrink rare joint tumors without surgery
- New drug hope for rare joint tumor patients who Can't have surgery
- Leukemia drug shows promise against rare joint tumors
- New drug shows promise for rare joint tumor in early trial